Posted by Michael Wonder on 22 Sep 2021
FDA approves ruxolitinib for chronic graft-versus-host disease
22 September 2021 - Today the Food and Drug Administration approved ruxolitinib (Jakafi, Incyte) for chronic graft-versus-host disease after failure of one or two lines of systemic therapy in adult and paediatric patients 12 years and older.
Efficacy was evaluated in REACH-3, a randomized, open-label, multicenter clinical trial of ruxolitinib compared to best available therapy for corticosteroid refractory chronic graft-versus-host disease after allogeneic stem cell transplantation.
